HD5 TFA
Based on 1 Customer Validation
HD5 TFA is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 TFA binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 TFA can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer.
For research use only. We do not sell to patients.
- Purity: 95.30%
- Formula: C144H238N50O45S6·xC2HF3O2
- Molecular Weight:3582.13 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
HD5 TFA binds with high affinity to the ligand-binding domain of host cell ACE2, competitively blocking and shielding the receptor to prevent SARS-CoV-2 recognition and infection of host cells[1].
HD5 (20 µM) TFA binds to regions of HPV16 L1 and L2 capsid proteins[2].
HD5 (15 μM; 5 days) TFA significantly inhibits the spread and cytolytic activity of PtDd-deficient mut-Ad3GFP in A549 cells, while only minimally impacting PtDd-producing wt-Ad3GFP[3].
HD5 (0.1 μM) TFA binds to HAdV3 penton base, fiber, fiber knob, and multimeric penton base-containing structures (PtDd and virion-associated penton bases) in a Western blot assay[3].
HD5 TFA significantly inhibits progeny virus production and spread of PtDd-deficient mut-Ad3GFP in Caco-2 and T84 cells, while PtDd-producing wt-Ad3GFP is unaffected[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 3582.13 (free base)
-
Formula C144H238N50O45S6·xC2HF3O2
-
Color White to light yellow
-
Sequence
Ala-Thr-Cys-Tyr-Cys-Arg-Thr-Gly-Arg-Cys-Ala-Thr-Arg-Glu-Ser-Leu-Ser-Gly-Val-Cys-Glu-Ile-Ser-Gly-Arg-Leu-Tyr-Arg-Leu-Cys-Cys-Arg (disulfide bridge:Cys3-Cys31,Cys5-Cys20,Cys10-Cys30)
-
Sequence Shortening
ATCYCRTGRCATRESLSGVCEISGRLYRLCCR (disulfide bridge:Cys3-Cys31,Cys5-Cys20,Cys10-Cys30)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : ≥ 100 mg/mL
* "≥" means soluble, but saturation unknown.
Purity & Documentation
-
Data Sheet (294 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Mahendran ASK, et al. The Potential of Antiviral Peptides as COVID-19 Therapeutics. Front Pharmacol. 2020 Sep 15;11:575444. doi: 10.3389/fphar.2020.575444. [Content Brief]
[2]. Gulati NM, et al. α-Defensin HD5 Stabilizes Human Papillomavirus 16 Capsid/Core Interactions. Pathog Immun. 2019 Sep 12;4(2):196-234. [Content Brief]
[3]. Vragniau C, et al. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol. 2017;91(6):e02030-16. Published 2017 Feb 28. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz